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Is Renervation an Issue?Marcos Rothstein, MDA lthough pharmacological antihypertensivetherapy effectively controls blood pressure(BP) in over 90% of patients with hyperten-
sion, there is an unmet need for a large segment of
the population who are at risk. The body of evidence
linking enhanced sympathetic nerve activation as a
signiﬁcant contributor to higher BP makes renal
denervation (RDN) an alternative target.
Catheter-based RDN has been shown to signiﬁ-
cantly reduce BP in the SYMPLICITY HTN-1 and
SYMPLICITY HTN-2 trials, also demonstrating the
safety of the procedure. As stated by Tellez et al. (1),
SYMPLICITY HTN-3—the ﬁrst prospective, sham-
controlled, randomized, double-blinded RDN study—
failed to meet its primary or secondary efﬁcacy
points. Many possible explanations for the disap-
pointing results have been put forth. The publication
of SYMPLICITY HTN-3 effectively halted most
ongoing studies and research in the ﬁeld. Of all likely
explanations, the largest criticisms relate to the
misunderstanding of renal nerve anatomy and sub-
optimal catheter design. This was compounded by
inadequate operator technique and experience.SEE PAGE 288The perspective by Tellez et al. (1) in this issue of
JACC: Basic to Translational Science timely summa-
rized the current status of the RDN therapy. One of
their hypotheses is that the best surrogate for RDN,
that is, the reduction of post-procedure renal
norepinephrine (NE) levels, is not sensitive enough to
judge success. A possible counter argument and a
more pragmatic approach to measuring NE levels has
been suggested. Gal et al. (2) performed a human trial
where several patients underwent a pulse of high-
frequency renal nerve stimulation before and afterFrom the Forest Park Kidney Center, Washington University School of Medi
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sive response to the nerve stimulation was a mean-
ingful and practical way to test the success of the
procedure.
Tellez et al. (1) discuss in detail the effect of “neu-
romatous regeneration” as an important reason for the
failure of treatment despite delivering optimal ther-
apy. As supportive evidence is the publication from
Prochnau et al. (3), in which a decrease in ofﬁce BP was
noted only when an initial radiofrequency RDN in 10
“nonresponder” patients was followed by a second
procedure, in this case renal artery cryoablation.
Against their claim, however, is signiﬁcant evi-
dence from the RDN Global Registry with over 1,000
patients treated mostly with a monoelectrode cath-
eter. In 75% of the subjects, at 1 year post-procedure,
both ofﬁce and 24-h BP continued to drop (4).
Likewise, others using newer-generation, multielec-
trode catheters have found ongoing lower BP read-
ings up to 24 months following RDN. Although an
argument can be made about possible renervation, at
the present time there is no evidence that regener-
ated nerve ﬁbers will reactivate a signiﬁcant sym-
pathetic output.
Recent and comprehensive animal studies may
show the way toward future human trials. Mahfoud
et al. (5) examined the effect of different patterns of
lesion placement in swine. In their experiments,
performed at a single time, RDN efﬁcacy and consis-
tency was determined by a drop in renal tissue NE
and decreased renal axon density. The investigators
used the multielectrode Spyral catheter (Medtronic,
Minneapolis, Minnesota) that delivered 4 thermal
injuries at a time to the main renal artery and its
branches. This technique was highly effective in
ablating the biochemical and anatomical surrogates ofcine, St. Louis, Missouri. Dr. Rothstein has reported
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297sympathetic nerves. A double thermal injury to
the main renal artery failed to bring any further
inhibition.
The disappointing results of SYMPLICITY HTN-3
relate to lack of response to the initial RDN, not to a
gradual return to higher BPs, as Tellez et al. (1) imply.
With a new generation of radiofrequency and ultra-
sound devices, RDN needs to be a simpliﬁed, angio-
graphic event. A secondary procedure would be
difﬁcult to accept and increasingly onerous. Also, if
correct, the assumption by Tellez et al. (1) would
require any subsequent RDN to be applied at the
precise site where the initial thermal injury occurred.
There is no current imaging, biochemical, or func-
tional testing that could identify unequivocally the
site of a previous thermal injury, thus making their
hypothesis theoretical and impractical.In summary, the perspective by Tellez et al. (1)
adds to the notion that renal renervation could be
another contributor to the failure of RDN. It is far
more likely that lack of understanding of the anatomy
of renal nerves and less effective ﬁrst-generation
devices, coupled with poor technique and poor pa-
tient selection, were the culprits for the negative re-
sults of SYMPLICITY HTN-3.
Should renervation ever become an issue, such as
in patients where initial success is followed by an
increase in BP, future research should focus on ways
to identify the site of a previous injury.
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